WallStSmart

Gilead Sciences Inc (GILD)vsOccidental Petroleum Corporation (OXY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Gilead Sciences Inc generates 39% more annual revenue ($29.44B vs $21.12B). GILD leads profitability with a 28.9% profit margin vs 22.4%. GILD appears more attractively valued with a PEG of 0.38. GILD earns a higher WallStSmart Score of 72/100 (B).

GILD

Strong Buy

72

out of 100

Grade: B

Growth: 5.3Profit: 9.5Value: 8.7Quality: 5.8
Piotroski: 6/9Altman Z: 1.81

OXY

Strong Buy

65

out of 100

Grade: B-

Growth: 4.7Profit: 6.0Value: 5.3Quality: 3.8
Piotroski: 2/9Altman Z: 1.14
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GILDUndervalued (+44.2%)

Margin of Safety

+44.2%

Fair Value

$235.52

Current Price

$131.33

$104.19 discount

UndervaluedFair: $235.52Overvalued
OXYUndervalued (+28.5%)

Margin of Safety

+28.5%

Fair Value

$66.05

Current Price

$53.03

$13.02 discount

UndervaluedFair: $66.05Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GILD6 strengths · Avg: 9.3/10
PEG RatioValuation
0.3810/10

Growing faster than its price suggests

Return on EquityProfitability
40.7%10/10

Every $100 of equity generates 41 in profit

Operating MarginProfitability
37.4%10/10

Strong operational efficiency at 37.4%

Market CapQuality
$166.40B9/10

Large-cap with strong market position

Profit MarginProfitability
28.9%9/10

Keeps 29 of every $100 in revenue as profit

EPS GrowthGrowth
23.4%8/10

Earnings expanding 23.4% YoY

OXY4 strengths · Avg: 9.0/10
EPS GrowthGrowth
315.6%10/10

Earnings expanding 315.6% YoY

Market CapQuality
$53.65B9/10

Large-cap with strong market position

Profit MarginProfitability
22.4%9/10

Keeps 22 of every $100 in revenue as profit

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

Areas to Watch

GILD2 concerns · Avg: 4.0/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Altman Z-ScoreHealth
1.814/10

Grey zone — moderate risk

OXY4 concerns · Avg: 2.5/10
Return on EquityProfitability
4.0%3/10

ROE of 4.0% — below average capital efficiency

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
72.9x2/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
-8.3%2/10

Revenue declined 8.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : GILD

The strongest argument for GILD centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 28.9% and operating margin at 37.4%. PEG of 0.38 suggests the stock is reasonably priced for its growth.

Bull Case : OXY

The strongest argument for OXY centers on EPS Growth, Market Cap, Profit Margin. Profitability is solid with margins at 22.4% and operating margin at 17.7%. PEG of 1.21 suggests the stock is reasonably priced for its growth.

Bear Case : GILD

The primary concerns for GILD are Revenue Growth, Altman Z-Score.

Bear Case : OXY

The primary concerns for OXY are Return on Equity, Piotroski F-Score, P/E Ratio. A P/E of 72.9x leaves little room for execution misses.

Key Dynamics to Monitor

GILD profiles as a value stock while OXY is a declining play — different risk/reward profiles.

GILD carries more volatility with a beta of 0.33 — expect wider price swings.

GILD is growing revenue faster at 4.7% — sustainability is the question.

GILD generates stronger free cash flow (2.4B), providing more financial flexibility.

Bottom Line

GILD scores higher overall (72/100 vs 65/100), backed by strong 28.9% margins. OXY offers better value entry with a 28.5% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Gilead Sciences Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

Occidental Petroleum Corporation

ENERGY · OIL & GAS E&P · USA

Occidental Petroleum Corporation is an American company engaged in hydrocarbon exploration in the United States, the Middle East, and Colombia as well as petrochemical manufacturing in the United States, Canada, and Chile.

Want to dig deeper into these stocks?